In addition, recent unbiased clustered regularly interspaced palindromic repeat (CRISPR)-based genome-wide loss-of-function screens have identified the TRAIL-TRAIL receptor axis as a critical determinant of the therapeutic response of cancer cells to CAR-T cell immunotherapy [4,5]. Here, TNFSF10 is linked to cancer.